Though still haunted by questions about its management's handling of flu vaccine production, Chiron Corp. got a not-unexpected Halloween treat from Novartis AG, which upped to $5.1 billion its offer to buy out the company - and this time Chiron is recommending that shareholders approve. (BioWorld Today) Read More